PUBLIC COMPANY
save$TARSTarsus Pharmaceuticals, Inc.
$TARS71.51+0.03%Irvine, CA, USupdated 3h ago
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Phase 21Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
- phase2Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
- phase2Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
- phase4Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
- phase2A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
- phase1A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects
- phase2Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
- phase3Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 20, 26SELLNeervannan Seshadri· Chief Operating Officer−$200K↗
- Mar 19, 26SELLAzamian Bobak R.· President/CEO and Board Chair−$802K↗
- Mar 19, 26SELLNeervannan Seshadri· Chief Operating Officer−$307K↗
- Mar 19, 26SELLMottiwala Aziz· Chief Commercial Officer−$297K↗
- Mar 19, 26SELLWahl Bryan· General Counsel−$283K↗
- Mar 19, 26SELLWhitfield Dianne C.· Chief Human Resources Officer−$280K↗
- Mar 19, 26SELLFarrow Jeffrey S· See Remarks−$146K↗
- Mar 19, 26SELLLin Elizabeth Yeu· Chief Medical Officer−$26K↗
- Mar 18, 26SELLAzamian Bobak R.· President/CEO and Board Chair−$802K↗
- Mar 18, 26SELLMottiwala Aziz· Chief Commercial Officer−$298K↗
- Mar 18, 26SELLWahl Bryan· General Counsel−$283K↗
- Mar 18, 26SELLWhitfield Dianne C.· Chief Human Resources Officer−$280K↗
- Mar 18, 26SELLNeervannan Seshadri· Chief Operating Officer−$248K↗
- Mar 18, 26SELLFarrow Jeffrey S· See Remarks−$147K↗
- Mar 18, 26SELLLin Elizabeth Yeu· Chief Medical Officer−$26K↗
- Mar 17, 26SELLAzamian Bobak R.· President/CEO and Board Chair−$762K↗
- Mar 17, 26SELLMottiwala Aziz· Chief Commercial Officer−$298K↗
- Mar 17, 26SELLWahl Bryan· General Counsel−$284K↗
- Mar 17, 26SELLWhitfield Dianne C.· Chief Human Resources Officer−$280K↗
- Mar 17, 26SELLNeervannan Seshadri· Chief Operating Officer−$217K↗
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800MAlkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”biopharma_dive · 14d ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 1mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that